AptarGroup, Inc.
Thesis
AptarGroup is a market leader in packaging solutions across pharma, beauty, and food sectors, with a strong growth outlook driven by its shift towards the higher-margin pharma segment. The company is expected to achieve mid-high single digit revenue growth and margin expansion, particularly as it capitalizes on trends in respiratory diseases and injectable devices. The target price of $167.42 reflects a CAGR of 9.4%, indicating solid long-term value.
Did it work?
The long thesis called for mid-high single digit revenue growth, margin expansion, and appreciation toward a $167.42 target implying a ~9.4% CAGR. Instead, 28 months later the stock is down 3.8%, the opposite direction of the expected compounding appreciation and roughly 20+ percentage points short of where the CAGR target implied by now. While the thesis did not state an explicit horizon and the fundamental claims (pharma-driven growth, margin expansion) cannot be verified from the data given, the price trajectory over a substantial portion of any plausible multi-year horizon clearly contradicts the thesis so far.